Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CVS HEALTH Corp
Report date April 01, 2017 · Filed April 04, 2017
Section 16 reporting ended · disclosed 2017-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,656 |
Ending reported balance
After 2017-04-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-04-01 · Tax withholding · Disposed 1,129 · Balance 13,252 F1: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock unit award. Row 2 · 2017-04-02 · Tax withholding · Disposed 1,596 · Balance 11,656 |
| Common Stock (restricted)SEC Table I · non-derivative | Direct | 16,433 |
Reported balance
After 2017-04-03 transaction · row 3
1 source rowRow 3 · 2017-04-03 · Grant · Acquired 4,804 · Balance 16,433 F2: Consists of restricted stock units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 50% on 4/3/2020 and 50% on 4/3/2022. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $78.05 · Expires 2024-04-03 | Direct | 37,567 |
Reported balance
After 2017-04-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-03 · Grant · Acquired 37,567 · Balance 37,567 F3: Option becomes exercisable in four equal annual installments, commencing 4/3/2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $36.96 · Expires 2019-09-01 | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-04-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 0 F4: Option became exercisable in three equal annual installments, commencing 9/1/2012. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $54.53 · Expires 2020-04-01 | Direct | 11,802 |
Reported balance
Holding disclosure · report date 2017-04-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 11,802 F5: Option became exercisable in four equal annual installments, commencing 4/1/2014. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $74.29 · Expires 2021-04-01 | Direct | 29,373 |
Reported balance
Holding disclosure · report date 2017-04-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 29,373 F6: Option became exercisable in four equal annual installments, commencing 4/1/2015. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $102.26 · Expires 2022-04-01 | Direct | 23,968 |
Reported balance
Holding disclosure · report date 2017-04-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 23,968 F7: Option became exercisable in four equal annual installments, commencing 4/1/2016. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $104.82 · Expires 2023-04-01 | Direct | 23,301 |
Reported balance
Holding disclosure · report date 2017-04-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 23,301 F8: Option became exercisable in four equal annual installments, commencing 4/1/2017. |
| Stock UnitSEC Table I · non-derivative | Direct | 10,144.5863 |
Reported balance
Holding disclosure · report date 2017-04-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 10,144.5863 |
Filing footnotes · ownership attribution and instrument terms
F1: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock unit award.
F2: Consists of restricted stock units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 50% on 4/3/2020 and 50% on 4/3/2022.
F3: Option becomes exercisable in four equal annual installments, commencing 4/3/2018.
F4: Option became exercisable in three equal annual installments, commencing 9/1/2012.
F5: Option became exercisable in four equal annual installments, commencing 4/1/2014.
F6: Option became exercisable in four equal annual installments, commencing 4/1/2015.
F7: Option became exercisable in four equal annual installments, commencing 4/1/2016.
F8: Option became exercisable in four equal annual installments, commencing 4/1/2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2012 Filed Oct 5, 2012 20:09 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 9,020 | $36.96 | $333,379.20 |
DisclosureSEC source: 0001127602-12-028327 · form4.xml · nonDerivative · entry 1 Sussman Andrew · CIK 0001515706 · SVP & President, MinuteClinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,949.1861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2012 Filed Apr 4, 2012 20:47 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 26,619 | $45.07 Strike: $45.07 | $1,199,718.33 |
DisclosureSEC source: 0001127602-12-013316 · form4.xml · derivative · entry 4 Sussman Andrew · CIK 0001515706 · SVP & President, MinuteClinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,619 Underlying: Common Stock · 26,619 shares Expires 2019-04-02 F2 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/2/2013. Read SEC document |
| April 02, 2012 Filed Apr 4, 2012 20:47 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (restricted) | 6,657 | $45.07 | $300,030.99 |
DisclosureSEC source: 0001127602-12-013316 · form4.xml · nonDerivative · entry 1 Sussman Andrew · CIK 0001515706 · SVP & President, MinuteClinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,304 F1 · shares: Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 50% on 4/2/2015 and 50% on 4/2/2017. Read SEC document |
| April 01, 2011 Filed Apr 5, 2011 21:03 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (restricted) | 6,436 | $34.96 | $225,002.56 |
DisclosureSEC source: 0001127602-11-012457 · form4.xml · nonDerivative · entry 1 Sussman Andrew · CIK 0001515706 · SVP & President, MinuteClinic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,647 F1 · shares: Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/1/2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.